Phase 1 Study of Sorafenib in Combination with Bortezomib in Patients with Advanced Malignancies

BACKGROUND: Sorafenib (a VEGFR and multi-targeted kinase inhibitor) and Bortezomib (a proteasome inhibitor) have clinical antineoplastic activities as single agents, and combine synergistically in preclinical models. METHODS: This Phase I study was undertaken to define the toxicity and the maximum t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kumar, Shaji K., Jett, James, Marks, Randolph, Richardson, Ronald, Quevedo, Fernando, Moynihan, Timothy, Croghan, Gary, Markovic, Svetomir N., Bible, Keith C., Qin, Rui, Tan, Angelina, Molina, Julian, Kaufmann, Scott H., Erlichman, Charles, Adjei, Alex A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3779429/
https://ncbi.nlm.nih.gov/pubmed/23887852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0004-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak